Colon Cancer, Primary Tumour, Rectal Cancer
Conditions
Keywords
Surgery, Chemotherapy
Brief summary
The clinical benefit of resection of the primary tumour in patients with synchronous unresectable metastases is not known. In the literature studies usually describe retrospective selected patients with synchronous metastases treated with or without resection of the primary tumour. All these studies are biased in patient selection and there are no prospective randomized studies on this topic. In patients with few or absent symptoms of the primary tumour, arguments both in favour and against initial resection have been presented, and therefore a randomized trial is warranted. Although recent publications suggest that resection of the primary tumour in synchronous metastasized colon cancer patients might not be necessary, this appears to be based on feasibility and not on clinical outcome. Several studies comparing large groups of patients with or without resection of the primary tumour suggest an improved survival when the primary tumour is resected. A potential benefit of resection of the primary tumour is to prevent complications of the primary tumour during chemotherapy treatment or during later stages of the disease. A recent analysis of the CAIRO and CAIRO2 data showed that metastatic colon cancer patients who had a resection of the primary tumour prior to study entry, had an improved survival compared to patients without a resection of the primary tumour. However, these patients were selected after the primary tumour was resected and therefore these results are not corrected for surgical morbidity and mortality. The investigators here propose a randomized trial in order to demonstrate that resection of the primary tumour does improve overall survival.
Interventions
PROCEDURESurgery of the primary tumour
Surgical resection of the colon tumour
First line fluoropyrimidine-based chemotherapy with bevacizumab. The chemotherapy regimen is to the discretion of the local investigator, who may choose between: 5FU/LV or capecitabine or capecitabine + oxaliplatin(CAPOX)or 5FU + oxaliplatin(FOLFOX 4 or FOLFOX 7)or 5FU + irinotecan (FOLFIRI) or capecitabine + irinotecan(CAPIRI)
Sponsors
Hoffmann-La Roche
Dutch Colorectal Cancer Group
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological proof of colorectal cancer * Resectable primary tumour in situ with unresectable distant metastases * No indication for neo-adjuvant (chemo)radiation * No severe signs or symptoms related to the primary tumour (i.e. severe bleeding, obstruction, severe abdominal pain) that require immediate surgery or other symptomatic treatment (e.g. stenting) * No prior systemic treatment for advanced disease * Age ≥ 18 years * WHO performance status 0-2 * Laboratory values obtained ≤ 4 weeks prior to randomization: Adequate bone marrow function (Hb ≥ 6.0 mmol/L, absolute neutrophil count ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L), renal function (serum creatinine ≤ 1.5x ULN and creatinine clearance, Cockroft formula, ≥ 30 ml/min), liver function (serum bilirubin ≤ 2 x ULN, serum transaminases ≤ 3 x ULN without presence of liver metastases or ≤ 5x ULN with presence of liver metastases) * Expected adequacy of follow-up * Written informed consent * CT scan abdomen and CT thorax/X-thorax performed ≤ 4 weeks prior to randomization
Exclusion criteria
* Pregnancy, lactation * Unresectable primary tumour (i.e. neurovascular encasement, substantial ingrowth in pancreatic head), or any condition preventing the safety or feasibility of resection of the primary tumour, i.e. massive ascites or extensive peritoneal disease * Requirement of neoadjuvant (chmo)radiation therapy * Second primary malignancy within the past 5 years with the exception of adequately treated in situ carcinoma of any organ or basal cell carcinoma of the skin * Any medical condition that prevents the safe administration of systemic treatment * Previous intolerance of fluoropyrimidines, known dihydropyrimidine dehydrogenase (DPD) deficiency * Planned radical resection of all metastatic disease * Uncontrolled hypertension, i.e. values consistently \> 150/100 mmHg * Use of ≥ 3 antihypertensive drugs * Significant cardiovascular disease \< 1 yr before randomization (symptomatic congestive heart failure, myocardial infarction, unstable angina pectoris, serious uncontrolled cardiac arrhythmia, cerebro vascular event) * Chronic active infection * Concurrent treatment with any other anti-cancer therapy as described per protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | Time from randomisation until death, assessed up to 5 years | Overall survival of the intent-to-treat population |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cost-benefit analyses | Until end of first-line systemic treatment | — |
| Patients requiring resection of the primary tumour in the non-resection arm | Time from randomisation until death, assessed up to 5 years | Number of patients requiring resection of the primary tumour in the non-resection arm |
| Progression-free survival | Time from randomisation until first progression or death whichever comes first, asessed up to 5 years | — |
| Response to chemotherapy | Fist-line chemotherapy, assessed until progression | Response rate according to RECIST 1.1 |
| Interval between randomization and initiation of systemic treatment | Number of days between randomization and initiation of systemic treatment | — |
| Surgery related morbidity and mortality | 30 days | — |
| Quality of life | Every 6 months from randomisation until first progression | EORTC QLQ-C30 and CR38 |
| Overall survival in patients in whom treatment according to protocol was initiated | Time form randomisation until death, assessed up to 5 years | Having received at least one cycle of systemic treatment in arm A and surgery in arm B |
| Systemic therapy related toxicity | Every 3 weeks during first-line treatment | Adverse events grade 3-4 according to NCI-CTC 4.0 |
Countries
Denmark, Netherlands
Outcome results
None listed